Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Therapeutic Advances in Respiratory Disease|September 6, 2013
Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidenceKavitha Kotha, John P ClancyPediatric Pulmonology|October 24, 2020
The respiratory impact of novel therapies for spinal muscular atrophyGrace R Paul, Courtney Gushue, Kavitha Kotha, et al.Chest|January 10, 2021
A 17-Year-Old With Becker Muscular Dystrophy and Unusual Polysomnography FindingsGrace R Paul, Rami N Khayat, Kavitha Kotha, et al.The Laryngoscope|December 4, 2025
Elexacaftor-Tezacaftor-Ivacaftor Reduces Revision Sinus Surgery in People With Cystic FibrosisAmy Lin, Makanko Komara, Isaac Kistler, et al.Pulmonary Pharmacology & Therapeutics|February 20, 2025
Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosisShahid Sheikh, Melissa Holtzlander, Mariah Eisner, et al.Critical Care Medicine|June 28, 2011
Metabolic effects of albumin therapy in acute lung injury measured by proton nuclear magnetic resonance spectroscopy of plasma: a pilot studyYoungja Park, Dean P Jones, Thomas R Ziegler, et al.The Journal of Asthma : Official Journal of the Association for the Care of Asthma|November 11, 2016
Improved quality-of-life of caregivers of children with asthma through guideline-based managementShahid I Sheikh, Judy Pitts, Nancy A Ryan-Wenger, et al.Respiratory Medicine|July 30, 2025
Real -world impact of previous exposure to CFTR modulators on clinical parameters and chronic sinus disease in people with cystic fibrosis on elexacaftor-tezacaftor-ivacaftorMelissa Holtzlander, Meredith Lind, Mariah Eisner, et al.Respiratory Medicine|July 31, 2026
Real-world Efficacy, Safety and Heterogenicity of Efficacy of Elexacaftor-Tezacaftor-Ivacaftor in Younger Children (6-11 Years Old) with Cystic FibrosisShahid Sheikh, Melissa Holtzlander, Mariah Eisner, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 27, 2015
Concentration of fractional excretion of nitric oxide (FENO): A potential airway biomarker of restored CFTR functionKavitha Kotha, Rhonda D Szczesniak, Anjaparavanda P Naren, et al.Pageof 2